Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03920618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

Study acronym: HBV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 29, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 31, 2023 to Dec 31, 2024
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Start date: Feb 1, 2019 to Feb 21, 2019
    • Eligibility criteria revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
Trial Details
NCT Number NCT03920618
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions
(from sponsor)		 Hepatitis B, Acute-On-Chronic Liver Failure
Related terms Acute-On-Chronic Liver Failure, Hepatitis B
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov